This segment focuses on the research, development, and commercialization of oral therapies for the treatment of HAE attacks. KalVista's lead product, sebetralstat (EKTERLY), is an oral plasma kallikrein inhibitor designed for on-demand treatment of acute HAE attacks. Research and development activities include Phase 3 clinical trials (KONFIDENT) to evaluate the efficacy and safety of sebetralstat. The company utilizes small molecule protease inhibitors as the core technology. The patient impact is significant, offering a potential alternative to injectable treatments and improving the quality of life for HAE patients. Market positioning is strong, with a focus on providing a convenient and effective oral treatment option. Future opportunities include expanding the label to include pediatric patients and exploring additional indications. Regulatory aspects involve obtaining approvals from regulatory bodies like the FDA and MHRA. Partnerships include licensing agreements with companies like Pendopharm to commercialize sebetralstat in Canada.

This segment is dedicated to the development of small molecule plasma kallikrein inhibitors for the treatment of DME. The primary focus is on KVD001, a plasma kallikrein inhibitor that has completed a Phase II clinical trial. Research and development efforts involve conducting clinical trials to assess the efficacy and safety of KVD001 in DME patients. The company leverages its expertise in small molecule drug discovery and development. The therapeutic area addresses a significant unmet medical need, aiming to improve vision and reduce the progression of DME. Market positioning is based on providing an innovative treatment option for DME. Future opportunities include advancing KVD001 through later-stage clinical trials and potentially expanding the product pipeline. Regulatory aspects involve obtaining necessary approvals from regulatory agencies. The company is actively seeking partnerships to further develop and commercialize its DME product candidates.